ERBB2 and ovarian carcinoma: In breast and ovarian cancers, HER2 overexpression (HER2+) predicts for a poor clinical outcome [10,11], findings that have prompted the development of HER2-targeted therapies, including small-molecule tyrosine kinase inhibitors (TKIs) designed to block the autokinase activity of the HER2 receptor.